Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Crucell, DSM Expand Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Crucell, DSM Expand Development Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Biologics and Crucell have entered an agreement to expand the existing commercial relationship for their PER.C6 collaboration to include new classes of proteins, including biosimilar protein products. As part of the agreement, Crucell received an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.

Since December 2002, the two companies jointly outlicense PER.C6 human cell line to third parties as a production platform for monoclonal antibodies and recombinant proteins. They recently established the PERCIVIA PER.C6 Development Center in Cambridge, MA as a joint venture to further develop the PER.C6 cell line and to provide production solutions for pharmaceutical proteins to licensees using the PER.C6 human cell line in the biotech industry.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters